---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-043500"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:40:59.418811+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling

## Summary
- GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.
- In NHPs, up to 51% precise editing of liver cells with surrogate H1069Q Prime Editor; no off-target edits detected.
- IND-enabling activities for Wilson's Disease program to start in 4Q 2024; IND/CTA filing expected 1H 2026.
- GSD1b program data: up to 85% precise liver cell editing in NHPs, durable to 44 weeks, no safety concerns.
- Universal liver-targeted LNP platform shows modularity; can be adapted to other rare and non-rare liver indications.

## SEC filing metadata
- accession: 0001628280-24-043500
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/0001628280-24-043500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/prme-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-043500
- JSON: https://secwatch.observer/filing/0001628280-24-043500.json
- Plain text: https://secwatch.observer/filing/0001628280-24-043500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.